Drug intelligence / Profile preview

Equirab

Development stage
Unknown
Lead developer
Bharat Serums and Vaccines
Modality
Antibody-Based Therapeutics
Administration
Intramuscular, Infiltration
01

Overview

Equirab is an equine rabies immunoglobulin (ERIG) developed and manufactured by Bharat Serums and Vaccines Limited. It consists of purified polyclonal antibody fragments derived from the hyperimmune serum of horses immunized against the rabies virus. Indicated for post-exposure prophylaxis (PEP) of rabies, it provides immediate passive immunity by neutralizing the rabies virus at the site of exposure and systemically before the patient's own immune system can respond to vaccination. It is typically administered as a 40 IU/kg dose, with as much as possible infiltrated around the wound and the remainder given intramuscularly, always in conjunction with a rabies vaccine.

Brand names
Equirab
Other names
equine rabies immunoglobulinequine rabies antiserumERIGanti-rabies serumanti-rabies equine antiserum
02

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on Equirab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equirab.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call